{"symbol":"ABT","provider":"yahoo-finance","fetchedAt":"2025-12-24T01:49:26.844Z","asOfDate":"2025-12-23","articles":[{"id":"63ee0fbd-cdbd-33b4-8b57-e8f5deb2e4ce","title":"Abbott Stock May Benefit Following Volt PFA's FDA Approval","url":"https://finance.yahoo.com/news/abbott-stock-may-benefit-following-190800413.html","publisher":"Zacks","publishedAt":"2025-12-23T19:08:00.000Z","relatedTickers":[],"mainIdea":"Abbott Stock May Benefit Following Volt PFA's FDA Approval","summary":"Zacks: Abbott Stock May Benefit Following Volt PFA's FDA Approval. ABT wins FDA approval for its Volt PFA System for AFib, paving the way for U.S. launches and EU expansion after earlier CE Mark clearance."},{"id":"3c2d7175-535b-38cb-afb2-3450fcd6176e","title":"Is Abbott Laboratories Attractively Priced After Recent Share Price Gains And DCF Concerns?","url":"https://finance.yahoo.com/news/abbott-laboratories-attractively-priced-recent-171130725.html","publisher":"Simply Wall St.","publishedAt":"2025-12-23T17:11:30.000Z","relatedTickers":[],"mainIdea":"Is Abbott Laboratories Attractively Priced After Recent Share Price Gains And DCF Concerns?","summary":"Simply Wall St.: Is Abbott Laboratories Attractively Priced After Recent Share Price Gains And DCF Concerns?. If you have been wondering whether Abbott Laboratories is still a buy at around $125 a share, you are not alone. This is exactly the kind of stock where valuation really matters. Despite slipping about 2.5% over the last week and 2.3% over the past month, Abbott is still up 10.4% year to date and roughly 11.6% over the last year, which keeps it firmly on investors radar as a steady compounder. Recent attention on Abbott has centered on its medical devices and diagnostics businesses,..."},{"id":"d135979f-2f2e-3d34-8c21-ead313a82e7d","title":"This Dividend Stock Just Scored an FDA Win. Should You Buy Shares Now?","url":"https://finance.yahoo.com/m/d135979f-2f2e-3d34-8c21-ead313a82e7d/this-dividend-stock-just.html","publisher":"Barchart","publishedAt":"2025-12-23T16:45:53.000Z","relatedTickers":[],"mainIdea":"This Dividend Stock Just Scored an FDA Win. Should You Buy Shares Now?","summary":"Barchart: This Dividend Stock Just Scored an FDA Win. Should You Buy Shares Now?. Abbott’s latest regulatory progress supports its durable growth narrative. Is now the right time to revisit ABT shares?"},{"id":"8435fa37-6ced-3408-a5bf-6c2ca8f68c47","title":"Should You Hold On To BSX Stock Despite Its Premium Valuation?","url":"https://finance.yahoo.com/news/hold-bsx-stock-despite-premium-122000453.html","publisher":"Zacks","publishedAt":"2025-12-23T12:20:00.000Z","relatedTickers":["BSX","MDT"],"mainIdea":"Should You Hold On To BSX Stock Despite Its Premium Valuation?","summary":"Zacks: Should You Hold On To BSX Stock Despite Its Premium Valuation?. Boston Scientific trades at a premium, but strong momentum in WATCHMAN, EP and MedSurg growth keeps long-term shareholders in the game despite valuation risks. Related tickers mentioned: BSX, MDT."},{"id":"499c173b-44ea-35c3-8bd3-d5d3e30e8576","title":"Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?","url":"https://finance.yahoo.com/news/invest-ishares-u-medical-devices-112003907.html","publisher":"Zacks","publishedAt":"2025-12-23T11:20:03.000Z","relatedTickers":["BLK","IHI"],"mainIdea":"Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?","summary":"Zacks: Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?. Sector ETF report for IHI Related tickers mentioned: BLK, IHI."},{"id":"c6bd0bce-c51d-355c-85f9-1b39d7ffe9fd","title":"Abbott Wins FDA Clearance for Volt","url":"https://finance.yahoo.com/news/abbott-wins-fda-clearance-volt-111948093.html","publisher":"GuruFocus.com","publishedAt":"2025-12-23T11:19:48.000Z","relatedTickers":[],"mainIdea":"Abbott Wins FDA Clearance for Volt","summary":"GuruFocus.com: Abbott Wins FDA Clearance for Volt. New heart device targets atrial fibrillation"},{"id":"f6670b26-2896-30de-ba33-05989de94aaf","title":"Abbott Secures US FDA Approval for Volt Pulsed Field Ablation System for Heart Rhythm Disorder","url":"https://finance.yahoo.com/news/abbott-secures-us-fda-approval-154718614.html","publisher":"MT Newswires","publishedAt":"2025-12-22T15:47:18.000Z","relatedTickers":[],"mainIdea":"Abbott Secures US FDA Approval for Volt Pulsed Field Ablation System for Heart Rhythm Disorder","summary":"MT Newswires: Abbott Secures US FDA Approval for Volt Pulsed Field Ablation System for Heart Rhythm Disorder. Abbott (ABT) said Monday the US Food and Drug Administration approved its Volt pulsed field ablation"},{"id":"298717dd-1edc-3fb1-bf0e-d70363defe05","title":"Global Recreational Boats Industry Intelligence Report 2025-2032 - Electric Boats Propel Market Evolution: Fastest Growing Segment Driven by Sustainability Trends","url":"https://finance.yahoo.com/news/global-recreational-boats-industry-intelligence-142800010.html","publisher":"GlobeNewswire","publishedAt":"2025-12-22T14:28:00.000Z","relatedTickers":["BC","MBUU"],"mainIdea":"Global Recreational Boats Industry Intelligence Report 2025-2032 - Electric Boats Propel Market Evolution: Fastest Growing Segment Driven by Sustainability Trends","summary":"GlobeNewswire: Global Recreational Boats Industry Intelligence Report 2025-2032 - Electric Boats Propel Market Evolution: Fastest Growing Segment Driven by Sustainability Trends. Recreational Boat Market Recreational Boat Market Dublin, Dec. 22, 2025 (GLOBE NEWSWIRE) -- The \"Recreational Boat Market by Boat Type, Boat Size, Engine Location, Engine Type, Material, Activity Type, Power Source, Power Range, Distribution Channel, Region - Global Forecast to 2032\" has been added to ResearchAndMarkets.com's offering. This report covers the recreational boat market segmented by boat type, activity, size, material, engine location and type, power source and range, distribution c Related tickers mentioned: BC, MBUU."},{"id":"2ab1ecc0-ddb1-3cdd-abca-253afa3712c9","title":"Abbott's Volt™ Pulsed Field Ablation System Receives FDA Approval to Treat Patients with Atrial Fibrillation","url":"https://finance.yahoo.com/news/abbotts-volt-pulsed-field-ablation-140000872.html","publisher":"PR Newswire","publishedAt":"2025-12-22T14:00:00.000Z","relatedTickers":[],"mainIdea":"Abbott's Volt™ Pulsed Field Ablation System Receives FDA Approval to Treat Patients with Atrial Fibrillation","summary":"PR Newswire: Abbott's Volt™ Pulsed Field Ablation System Receives FDA Approval to Treat Patients with Atrial Fibrillation. Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) has approved the company's Volt™ PFA System to treat patients battling atrial fibrillation (AFib). Abbott will soon begin commercial PFA cases in the United States and will continue its expansion of sites in the European Union following Volt CE Mark approval earlier this year."}]}
